Mirodenafil
SK-3530 · Mvix · Mvix-S
Last updated
At a glance
Overview
Overview#
Mirodenafil (sold in Korea as Mvix and Mvix-S ODF) is a second-generation PDE5 inhibitor that physique-focused users reach for when tadalafil's 36-hour shadow is unwanted and sildenafil's PDE6 cross-reactivity (the blue-tint vision and harsher flushing) is a problem. The selectivity profile is the headline: ~48,000-fold PDE5-over-PDE1 selectivity and clean separation from PDE6, paired with a fast ~1.25 h Tmax and a short ~2.5 h half-life — among the shortest in the class.
The practical appeal for the bodybuilding and looksmaxxing community is twofold. On-demand at 50–100 mg, it delivers the standard PDE5I erection-quality and pump benefit with a clean offset by bedtime. At 25–50 mg daily, it covers on-cycle blood pressure, peripheral vasodilation, and BPH/LUTS overlap — the same playbook as daily low-dose tadalafil, but for users who don't want the long tail.
"Mirodenafil is a potent and highly selective phosphodiesterase type 5 inhibitor with a favorable pharmacokinetic profile, short half-life, and superior selectivity for PDE5 over PDE1 and PDE6." — Cho & Paick, Therapeutic Advances in Urology (2016)
The sections below cover documented mirodenafil dosage brackets, the on-demand vs daily-low-dose split, on-cycle protocols for BP and pump, how it stacks against tadalafil and sildenafil, side effects and the hard nitrate contraindication, and the sourcing reality outside Korea.
How Mirodenafil works
PDE5 Inhibition and the cGMP Cascade#
Mirodenafil is a competitive inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for hydrolyzing cyclic guanosine monophosphate (cGMP) in vascular and corporal smooth muscle. Sexual stimulation triggers nitric oxide (NO) release from cavernosal nerves and endothelium; NO activates soluble guanylate cyclase, which generates cGMP, which in turn drops intracellular calcium and relaxes the trabecular smooth muscle of the corpora cavernosa. Blood inflow rises, the venous outflow is mechanically compressed against the tunica albuginea, and an erection develops.
Mirodenafil does not initiate this cascade — it amplifies it. No NO signal, no effect. This is why it works "on demand with stimulation" rather than as a pharmacological switch, and why mismanaged estradiol or crashed NO production on a 19-nor cycle can blunt response even at full dose.
"Mirodenafil is a potent and highly selective phosphodiesterase type 5 inhibitor with a favorable pharmacokinetic profile, short half-life, and superior selectivity for PDE5 over PDE1 and PDE6." — Cho MC, Paick JS, Therapeutic Advances in Urology, 2016
Selectivity Profile vs Other PDE Isoforms#
The PDE family has eleven isoforms scattered across smooth muscle, retina, heart, and platelets. Side-effect differentiation between PDE5 inhibitors is largely a story about which off-target isoforms they hit.
- PDE6 (retinal photoreceptors): hitting it produces the "blue-tint" vision and photophobia famous from sildenafil. Mirodenafil's PDE5/PDE6 selectivity is substantially higher, which is why visual disturbances are rare in the trial data.
- PDE1 (vascular smooth muscle, brain): mirodenafil's PDE5/PDE1 selectivity has been reported at roughly 48,000-fold — a cleaner profile than sildenafil.
- PDE11 (skeletal muscle, prostate): tadalafil's affinity here is the leading hypothesis for its back/leg ache signature. Mirodenafil is not a meaningful PDE11 inhibitor at therapeutic exposures, which is why myalgia is not part of its side-effect pattern.
The practical takeaway for physique-focused users: mirodenafil is the PDE5 inhibitor to reach for when sildenafil produces visual artifacts and tadalafil produces back ache.
Pharmacokinetics and the Onset/Offset Window#
Mechanism alone doesn't explain how a compound feels — the kinetics do. Mirodenafil hits peak plasma concentration at roughly 1.25 hours and clears with a half-life near 2.5 hours, placing it among the shortest-acting agents in the class.
"Mirodenafil exhibits a rapid onset of action with a mean time to maximum plasma concentration (Tmax) of 1.25 hours and a relatively short half-life of 2.5 hours." — Cho MC, Paick JS, Therapeutics and Clinical Risk Management, 2014
Practically, this means the working window is roughly 4 hours from dose, with the peak effect concentrated in hours 1–3. There is no 36-hour "weekender" coverage as with tadalafil — the trade-off is a clean offset, no residual nasal congestion or flushing into the next day, and unimpaired nocturnal blood-pressure dipping during sleep. CYP3A4 handles the bulk of metabolism, so strong inhibitors (ketoconazole, ritonavir, grapefruit in volume) push exposure up and warrant dose reduction.
Smooth-Muscle Relaxation Beyond the Corpora#
PDE5 is expressed not just in cavernosal tissue but throughout the pelvic vasculature, prostatic stroma, bladder neck, and urethral smooth muscle — which is why mirodenafil has documented utility for lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia.
"Once-daily administration of 50 mg mirodenafil resulted in significant improvement of erectile function with a low incidence of treatment-related adverse events." — Paick JS, Kim SW, Park YK, et al., Journal of Sexual Medicine, 2013
For the lifter audience, the same mechanism is relevant for three off-label use cases:
- On-cycle blood pressure: chronic PDE5 inhibition modestly lowers systemic vascular resistance, useful against AAS-driven hypertension.
- Pump and peripheral vasodilation: enhanced cGMP signaling in arterial smooth muscle translates to greater intramuscular blood flow during training — the same logic the daily-tadalafil-for-pump crowd is already running.
- Scalp microcirculation: a softer rationale extrapolated mostly from tadalafil data, but the upstream mechanism (cGMP-mediated arteriolar relaxation) is shared.
Combination Pharmacology with α1-Blockers#
In men running PDE5 inhibition for both erectile and LUTS coverage, layering with an α1-adrenergic blocker (tamsulosin) addresses two distinct contributors to bladder outlet obstruction — smooth-muscle tone via PDE5/cGMP and α1-mediated sympathetic tone — without meaningful BP collision when initiation is staggered.
"Combination therapy of mirodenafil and α1-blocker significantly improved both LUTS and erectile function without increasing the incidence of adverse events." — Paick JS, Kim SW, Yang DY, et al., International Journal of Impotence Research, 2011
The mechanism that makes mirodenafil useful is also the mechanism behind its single hard contraindication: organic nitrates and NO donors (nitroglycerin, isosorbide, amyl nitrite/"poppers") combined with any PDE5 inhibitor produce uncontrolled cGMP accumulation and catastrophic hypotension. This is the line that does not get crossed regardless of dose, formulation, or experience level.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 25–50 mg | As needed | Documented entry-level range |
| Mid | 50–100 mg | As needed | Most commonly studied range |
| High | 50–100 mg | As needed | On-demand: 45–60 min pre-activity, max once per 24 h. Daily low-dose protocol (off-label vs Korean label, which approves 50 mg QD): 25–50 mg every morning for chronic BP, pump, and BPH coverage. |
Cycle length & outcomes
Documented cycle
1–52 weeks
Plateau after
52 wks
Cycle Notes#
Mirodenafil is non-hormonal, non-suppressive, and does not require loading, tapering, or PCT. "Cycle length" here refers to how long a protocol is run continuously — the compound can be administered on-demand indefinitely, or daily for as long as the underlying use-case (on-cycle BP, BPH overlap, AAS-related erectile drag) is active.
Mirodenafil Dosage by Goal#
| Goal | Protocol Length | Dose & Timing |
|---|---|---|
| On-demand erectile response | Indefinite (per-event) | 50–100 mg, 45–60 min pre-activity, max 1×/24 h |
| Daily BP and pump support on cycle | Length of the AAS cycle (8–20 weeks typical) | 25–50 mg every morning |
| AAS-related ED recovery (19-nors, crashed E2) | 4–12 weeks while E2 is corrected | 25 mg daily + 50 mg on-demand |
| LUTS / BPH overlap (older TRT users) | Continuous (≥12 weeks to assess IPSS shift) | 50 mg daily |
| Pre-workout pump (community pattern) | Per-session | 50 mg, ~60 min pre-training |
Onset and Duration#
Tmax sits at ~1.25 hours and the half-life is ~2.5 hours, placing mirodenafil between sildenafil and avanafil for time-to-peak and well short of tadalafil for duration.
"Mirodenafil exhibits a rapid onset of action with a mean time to maximum plasma concentration (Tmax) of 1.25 hours and a relatively short half-life of 2.5 hours." — Cho & Paick, Therapeutics and Clinical Risk Management (2014)
Practical implication: usable activity window is roughly 4 hours from a single on-demand dose. A high-fat meal in the 2 h before dosing will delay Tmax — the protocol calls for an empty stomach when a tight onset matters.
Loading and Tapering#
There is no loading phase. PDE5 inhibition is immediate and dose-dependent — the first 50 mg administered produces the same response as the fiftieth. There is no tapering requirement on discontinuation; cGMP signaling reverts to baseline within a few half-lives (roughly 12–15 hours after the last dose).
The once-daily 50 mg protocol reaches functional steady state within ~24 hours given the short half-life, so the "daily user" doesn't wait two weeks for benefit the way tadalafil 5 mg users sometimes describe.
"Once-daily administration of 50 mg mirodenafil resulted in significant improvement of erectile function with a low incidence of treatment-related adverse events." — Paick et al., Journal of Sexual Medicine (2013)
On-Cycle Bloodwork Cadence#
Mirodenafil itself does not require monitoring labs. When run alongside AAS, the usual on-cycle panel applies:
- Resting BP log — weekly, ideally morning and evening. PDE5 inhibition lowers BP modestly; this is a feature on cycle, but users starting from already-low pressures titrate from 25 mg.
- Lipid panel — baseline and mid-cycle (AAS-driven, not mirodenafil-driven)
- Hematocrit — baseline and every 8–12 weeks on TRT/AAS
- Liver enzymes — only relevant if hepatic impairment is suspected or strong CYP3A4 inhibitors are co-administered
Protocol Duration Ceiling#
The Korean label supports continuous daily 50 mg dosing without a defined endpoint, and the trial data covers multi-month exposure without cumulative toxicity signals.
"Mirodenafil is a potent and highly selective phosphodiesterase type 5 inhibitor with a favorable pharmacokinetic profile, short half-life, and superior selectivity for PDE5 over PDE1 and PDE6." — Cho & Paick, Therapeutic Advances in Urology (2016)
In practice, daily protocols are run for the length of the underlying need: an 8–20 week AAS cycle, a 12+ week BPH symptom-management window, or indefinitely as a quality-of-life adjunct. On-demand use carries no cycle length at all — it is per-event, with the 24-hour redosing ceiling being the only hard rule.
Risks & mistakes
Common (most users)#
Tolerability in the published trials is good — adverse events at 50–100 mg were predominantly mild and self-limiting (Cho & Paick, 2016). The frequent stuff:
- Facial flushing (6.7–24.1%) — dose-dependent; cooler ambient temperature and adequate hydration blunt it. Drops sharply at the 25–50 mg daily bracket vs 100 mg on-demand.
- Headache (1.8–14.8%) — typically frontal, peaks around Tmax (~1.25 h), clears with the half-life (~2.5 h). Acetaminophen tolerates well; NSAIDs work but stack onto any AAS-related GI/renal load. Users prone to PDE5I headache often do better on mirodenafil than tadalafil simply because the offset is faster.
- Nasal congestion — class effect from vasodilation of nasal mucosa. Oxymetazoline sparingly is fine; chronic daily-low-dose users adapt within 1–2 weeks.
- Dyspepsia / mild nausea — low single-digit incidence. Pairing the dose with a light, low-fat snack rather than a heavy meal preserves Tmax and settles the stomach.
- Conjunctival hyperemia (red eyes) — less than sildenafil thanks to superior PDE6 selectivity, but present. Self-limiting.
- Back / muscle ache — uncommon; mirodenafil does not appear to be a meaningful PDE11 hitter at therapeutic exposures, so the tadalafil-pattern lumbar ache is rarely the limiting factor.
Uncommon (dose-dependent or individual)#
- Symptomatic hypotension / lightheadedness on standing — more likely in users already running aggressive antihypertensives, daily tadalafil overlap, or low resting pressures. Titrate from 25 mg, log resting BP for the first two weeks of a daily protocol, and avoid stacking PDE5 inhibitors.
- Visual disturbance (blue-tint, photophobia) — rare given the PDE6 selectivity advantage, but reported. If it appears, drop the dose or rotate to tadalafil.
- Tachycardia / palpitations — usually anxiety-mediated rather than directly drug-mediated, but worth checking resting HR and BP. On AAS with elevated hematocrit, the combined load on the cardiovascular system is the real signal, not the PDE5I.
- Prolonged erection (>4 h, not priapism) — uncommon at label doses; more likely with stacked PDE5 inhibitors or strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit in volume) raising exposure. Dose reduction warranted when those are concurrent.
- Hearing changes (tinnitus, sudden sensorineural hearing loss) — a class-label warning across PDE5 inhibitors. Genuinely rare but a stop-and-evaluate signal if it occurs.
Bloodwork to keep tabs on at the daily-low-dose tier: resting BP log, lipid panel, and — for users running this alongside AAS — hematocrit. PDE5 inhibition modestly lowers BP, which is generally a feature on cycle, but the combination with crashed E2 or aggressive diuretic use can produce orthostatic episodes.
Rare but serious#
- Priapism (erection >4 h) — urological emergency. Risk rises with sickle-cell disease, multiple myeloma, leukemia, or CYP3A4-induced overexposure. Stop the compound and seek care immediately.
- NAION (non-arteritic anterior ischemic optic neuropathy) — sudden painless vision loss in one eye. Class-label rare event across PDE5 inhibitors. Discontinue immediately.
- Sudden sensorineural hearing loss — abrupt unilateral hearing reduction ± tinnitus or vertigo. Discontinue immediately.
- Severe symptomatic hypotension — most often when an interacting drug has been overlooked (see contraindications). Syncope, chest pain, or persistent lightheadedness is a stop signal.
Hard contraindications#
These lines do not get crossed:
- Organic nitrates (nitroglycerin, isosorbide mono-/dinitrate) and nitric-oxide donors (amyl nitrite / "poppers", molsidomine) — combined PDE5 inhibition and NO donation produces severe, potentially fatal hypotension. Absolute contraindication. The "stack night" with poppers in a recreational context is the lethal combination users get killed by.
- Soluble guanylate cyclase stimulators (riociguat) — absolute contraindication.
- Other PDE5 inhibitors — do not overlap sildenafil, tadalafil, vardenafil, avanafil, or udenafil with mirodenafil. Pick one.
- Recent myocardial infarction, unstable angina, recent stroke, severe hypotension, severe hepatic impairment — avoid.
- Concurrent strong α1-blocker initiation — staggered start is the rule. Mirodenafil + tamsulosin is tolerated once both are stable (Paick et al., 2011), but layering a fresh α1-blocker onto an established PDE5I (or vice versa) without titration risks orthostatic collapse.
- Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice in volume) — exposure rises substantially; dose reduction required.
Gender, pregnancy, and PCT considerations#
Mirodenafil is non-hormonal — no HPTA suppression, no aromatization, no androgenic load — so no PCT is required and it can be layered onto or run after any AAS protocol without endocrine disruption. The documented use-case is male erectile and pelvic-vascular response; data in female subjects is limited and not the application this profile is written for. There is no virilization risk and no teratogenicity signal of clinical relevance, but pregnancy is simply outside the evidence base — the compound is not used in that population.
For users running mirodenafil to rescue erectile response on a 19-nor cycle (tren, nandrolone) or through a crashed-E2 episode: the PDE5I masks the symptom, it does not fix the upstream endocrine problem. Audit estradiol, prolactin, and SHBG; correct the cause; let the PDE5I carry the gap.
FAQ — Mirodenafil
Research & citations
5 studies cited on this page.
Conclusion
Mirodenafil is a niche but highly selective PDE5 inhibitor with rapid onset and a clean side-effect profile — the smart pick for users seeking both performance and aesthetics crossover, especially when standard options like tadalafil or sildenafil are not tolerated or desired.
Key takeaways:
- Documented on-demand dose: 50–100 mg, taken 45–60 minutes before activity; daily low-dose pattern (25–50 mg every morning) is described for chronic BP, pump, or LUTS support
- Rapid onset (Tmax ~1.25 h) and short half-life (~2.5 h) make it ideal for scenarios where quick onset and a short window of effect are preferred
- Clean PDE5 selectivity minimizes visual disturbances and myalgia — a solid call for users who experience "blue vision" from sildenafil or back pain with tadalafil
- Oral tablet and ODF formulations are bioequivalent; food can slightly delay onset but does not blunt efficacy
- Pairs well with TRT or AAS cycles, and slots into hair, prostate, and pre-pump stacks for aesthetics-driven protocols
- Absolute contraindication with nitrates, nitric oxide donors, or guanylate cyclase stimulators due to severe hypotension risk
For research applications where fast, on-demand vascular modulation is the goal, mirodenafil stands out as a precision tool in the PDE5 inhibitor class.